共刺激受体:肿瘤免疫疗法的潜在靶点

doi:10.11904/j.issn.1002-3070.2021.05.010

摘要/Abstract

摘要： 免疫细胞表面的共刺激受体对免疫细胞的活化、增殖及效应功能的发挥具有重要作用。在肿瘤中,共刺激受体经特异性激动性单克隆抗体激活后能增强免疫细胞的效应功能,促进对肿瘤细胞的杀伤,抑制肿瘤的生长,可作为抗肿瘤免疫疗法的靶点。本文就几种共刺激受体在生理条件下、肿瘤免疫及抗肿瘤免疫治疗中的作用进行了综述。

关键词: 肿瘤, 共刺激及抑制T细胞受体, 免疫疗法

Abstract: Co-stimulatory receptors on the surface of immune cells play important role in the activation,proliferation and effectors' function of immune cells.In tumors,co-stimulatory receptors can be activated by specific agonistic monoclonal antibodies to enhance the effectors' function of immune cells,promote the killing of tumor cells,inhibit tumor growth,and can be used as a target for anti-tumor immunotherapy.This article reviews the role of several co-stimulatory receptors in the physiological conditions,tumor immunology and anti-tumor immunotherapy.

Key words: Tumor, Co-stimulatory and inhibitory T-Cell receptors, Immunotherapy

中图分类号:

R730.51

张伟明, 孙坚萍, 赵艳. 共刺激受体:肿瘤免疫疗法的潜在靶点[J]. 实用肿瘤学杂志, 2021, 35(5): 441-446.

ZHANG Weiming, SUN Jianping, ZHAO Yan. Co-stimulatory receptors:potential targets for tumor immunotherapy[J]. Journal of Practical Oncology, 2021, 35(5): 441-446.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.05.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I5/441

参考文献

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 Chen L,Flies DB.Molecular mechanisms of T cell co-stimulation and co-inhibition[J].Nat Rev Immunol,2013,13(4):227-242.
3 Toor SM,Sasidharan Nair V,Decock J,et al.Immune checkpoints in the tumor microenvironment[J].Semin Cancer Biol,2020,65:1-12.
4 Andrews LP,Yano H,Vignali DAA.Inhibitory receptors and ligands beyond PD-1,PD-L1 and CTLA-4:breakthroughs or backups[J].Nat Immunol,2019,20(11):1425-1434.
5 Knee DA,Hewes B,Brogdon JL.Rationale for anti-GITR cancer immunotherapy[J].Eur J Cancer,2016,67:1-10.
6 Vence L,Bucktrout SL,Fernandez Curbelo I,et al.Characterization and comparison of GITR expression in solid tumors[J].Clin Cancer Res,2019,25(21):6501-6510.
7 Zhu MMT,Burugu S,Gao D,et al.Evaluation of glucocorticoid-induced TNF receptor(GITR)expression in breast cancer and across multiple tumor types[J].Mod Pathol,2020,33(9):1753-1763.
8 Buzzatti G,Dellepiane C,Del Mastro L.New emerging targets in cancer immunotherapy:the role of GITR[J].ESMO Open,2020,4(Suppl 3):e000738.
9 Zappasodi R,Sirard C,Li Y,et al.Rational design of anti-GITR-based combination immunotherapy[J].Nat Med,2019,25(5):759-766.
10 Makkouk A,Chester C,Kohrt HE.Rationale for anti-CD137 cancer immunotherapy[J].Eur J Cancer,2016,54:112-119.
11 Glorieux C,Huang P.CD137 expression in cancer cells:regulation and significance[J].Cancer Commun(Lond),2019,39(1):70.
12 Schmohl JU,Nuebling T,Wild J,et al.Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML[J].J Investig Med,2016,64(8):1252-1260.
13 Grimmig T,Gasser M,Moench R,et al.Expression of tumor-mediated CD137 ligand in human colon cancer indicates dual signaling effects[J].Oncoimmunology,2019,8(12):e1651622.
14 Etxeberria I,Glez-Vaz J,Teijeira Á,et al.New emerging targets in cancer immunotherapy:CD137/4-1BB costimulatory axis[J].ESMO Open,2020,4(Suppl 3):e000733.
15 Buchan SL,Rogel A,Al-Shamkhani A.The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy[J].Blood,2018,131(1):39-48.
16 Nuebling T,Schumacher CE,Hofmann M,et al.The immune checkpoint modulator OX40 and its ligand OX40L in NK-cell immunosurveillance and acute myeloid leukemia[J].Cancer Immunol Res,2018,6(2):209-221.
17 Rothfelder K,Hagelstein I,Roerden M,et al.Expression of the immune checkpoint modulator OX40 in acute lymphoblastic leukemia is associated with BCR-ABL positivity[J].Neoplasia,2018,20(11):1150-1160.
18 Xie K,Xu L,Wu H,et al.OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment,specific mutation signature,and poor prognosis[J].Oncoimmunology,2018,7(4):e1404214.
19 He Y,Zhang X,Jia K,et al.OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers[J].Transl Lung Cancer Res,2019,8(4):352-366.
20 Ramser M,Eichelberger S,Däster S,et al.High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy[J].BMC Cancer,2018,18(1):425.
21 Weixler B,Cremonesi E,Sorge R,et al.OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer[J].Oncotarget,2015,6(35):37588-37599.
22 Alves Costa Silva C,Facchinetti F,Routy B,et al.New pathways in immune stimulation:targeting OX40[J].ESMO Open,2020,5(1):e000573.
23 Starzer AM,Berghoff AS.New emerging targets in cancer immunotherapy:CD27(TNFRSF7)[J].ESMO Open,2020,4(Suppl 3):e000629.
24 Riether C,Schürch CM,Bührer ED,et al.CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia[J].J Exp Med,2017,214(2):359-380.
25 Chen D,Gerasimˇcik N,Camponeschi A,et al.CD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemia[J].Blood Cancer J,2017,7(6):e575.
26 Shan TT,Zhao X,Zhang Z,et al.Clinical significance of down-regulated CD70 and CD27 expression in poor prognosis of esophageal squamous cell carcinoma[J].Cancer Manag Res,2020,12:6909-6920.
27 Ge H,Mu L,Jin L,et al.Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM[J].Int J Cancer,2017,141(7):1434-1444.
28 Wensveen FM,Unger PP,Kragten NA,et al.CD70-driven costimulation induces survival or Fas-mediated apoptosis of T cells depending on antigenic load[J].J Immunol,2012,188(9):4256-4267.
29 Claus C,Riether C,Schürch C,et al.CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth[J].Cancer Res,2012,72(14):3664-3676.
30 Wasiuk A,Testa J,Weidlick J,et al.CD27-mediated regulatory T cell depletion and effector T cell costimulation both contribute to antitumor efficacy[J].J Immunol,2017,199(12):4110-4123.
31 Burris HA,Infante JR,Ansell SM,et al.Safety and activity of varlilumab,a novel and first-in-class agonist anti-CD27 antibody,in patients with advanced solid tumors[J].J Clin Oncol,2017,35(18):2028-2036.
32 Blazquez JL,Benyamine A,Pasero C,et al.New insights into the regulation of γδ T cells by BTN3A and other BTN/BTNL in tumor immunity[J].Front Immunol,2018,9:1601.
33 Zocchi MR,Costa D,Venè R,et al.Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity[J].Oncoimmunology,2017,6(3):e1278099.
34 Payne KK,Mine JA,Biswas S,et al.BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells[J].Science,2020,369(6506):942-949.
35 Benyamine A,Loncle C,Foucher E,et al.BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma(PDAC)[J].Oncoimmunology,2017,7(1):e1372080.
36 Zhu M,Yan C,Ren C,et al.Exome array analysis identifies variants in SPOCD1 and BTN3A2 that affect risk for gastric cancer[J].Gastroenterology,2017,152(8):2011-2021.
37 Benyamine A,Le Roy A,Mamessier E,et al.BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia[J].Oncoimmunology,2016,5(10):e1146843.
38 Laman JD,Claassen E,Noelle RJ.Functions of CD40 and its ligand,gp39(CD40L)[J].Crit Rev Immunol,2017,37(2-6):371-420.
39 Dimitrakopoulos FD,Kottorou AE,Antonacopoulou AG,et al.Expression of immune system-related membrane receptors CD40,RANK,BAFFR and LTβR is associated with clinical outcome of operated non-small-cell lung cancer patients[J].J Clin Med,2019,8(5):741.
40 Werner JM,Kuhl S,Ulrich K,et al.Expression of CD40 correlates negatively with overall and progression-free survival of low-and high-grade gliomas[J].World Neurosurg,2019,130:17-25.
41 Matsumura Y,Hiraoka K,Ishikawa K,et al.CD40 expression in human esophageal squamous cell carcinoma is associated with tumor progression and lymph node metastasis[J].Anticancer Res,2016,36(9):4467-4475.
42 Vonderheide RH.CD40 agonist antibodies in cancer immunotherapy[J].Annu Rev Med,2020,71:47-58.
43 Vonderheide RH,Flaherty KT,Khalil M,et al.Clinical activity and immune modulation in cancer patients treated with CP-870,893,a novel CD40 agonist monoclonal antibody[J].J Clin Oncol,2007,25(7):876-883.
44 Bajor DL,Mick R,Riese MJ,et al.Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma[J].Oncoimmunology,2018,7(10):e1468956.
45 Segal NH,He AR,Doi T,et al.Phase I study of single-agent utomilumab(PF-05082566),a 4-1BB/CD137 agonist,in patients with advanced cancer[J].Clin Cancer Res,2018,24(8):1816-1823.
46 Gopal AK,Levy R,Houot R,et al.First-in-human study of utomilumab,a 4-1BB/CD137 agonist,in combination with rituximab in patients with follicular and other CD20⁺ non-hodgkin lymphomas[J].Clin Cancer Res,2020,26(11):2524-2534.

[1]	符艳, 颜李丽, 王春雨, 符芳敏, 董华. 2010—2016年琼海市恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2021, 35(5): 396-401.
[2]	商昌权, 李国东, 魏九峰, 刘明. MCM蛋白在消化系统肿瘤的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 431-435.
[3]	隆园辉, 陈雪松. 心理应激对肿瘤微环境中免疫细胞影响的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 436-440.
[4]	张璐, 董振坤, 崔岩. 循环肿瘤DNA在肾癌中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 447-451.
[5]	金升烨, 庞达. 溶瘤病毒诱导肿瘤凋亡及激活抗肿瘤免疫机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 462-467.
[6]	范琳, 田霖丽, 刘鸣. 单细胞测序技术在头颈部恶性肿瘤中的研究与发展[J]. 实用肿瘤学杂志, 2021, 35(5): 472-475.
[7]	刘言玉, 李道娟, 梁迪, 师金, 靳晶, 单保恩, 贺宇彤. 2011—2016年河北省肿瘤登记地区食管癌发病和死亡流行情况分析[J]. 实用肿瘤学杂志, 2021, 35(4): 314-320.
[8]	王秦, 林玲, 蔡波, 陶长余, 武鸣, 韩仁强, 罗鹏飞, 俞浩, 缪伟刚, 周金意. 2015年江苏省脑和神经系统肿瘤流行现状及2006—2015年趋势分析[J]. 实用肿瘤学杂志, 2021, 35(4): 321-326.
[9]	武婧, 崔王飞, 曹凌, 郭雪蓉, 马朝辉, 王昕琛, 张瑞锋, 张永贞. 山西省肿瘤登记地区2016年上消化道癌发病与死亡情况分析[J]. 实用肿瘤学杂志, 2021, 35(4): 327-331.
[10]	任思颖, 陈杨, 石青萍, 朱云芳, 文洪梅. 云南省肿瘤登记地区2011—2016年肺癌发病和死亡特征及时间趋势[J]. 实用肿瘤学杂志, 2021, 35(4): 332-338.
[11]	董华, 王定彬, 华婧, 范康琼, 马楠楠, 王兴任. 2016年海南省肿瘤登记地区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2021, 35(4): 344-350.
[12]	刘双庆, 车德海, 孟庆威. 5-羟甲基胞嘧啶与肿瘤[J]. 实用肿瘤学杂志, 2021, 35(4): 386-390.
[13]	黄瑜, 刘玉琴, 丁高恒, 古扎努尔·尼牙孜, 王亮亮, 吴建军. 2009—2015年甘肃省肿瘤登记地区胆囊癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 193-199.
[14]	王亮亮, 丁高恒, 陈莉莉, 吴建军, 刘玉琴, 魏兴民. 2009—2015年甘肃省肿瘤登记地区胰腺癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 200-206.
[15]	郭伟, 朱奕潼, 丁高恒, 朱公建, 刘玉琴, 吴建军. 2009—2015年甘肃省肿瘤登记地区子宫体癌发病与死亡特征分析[J]. 实用肿瘤学杂志, 2021, 35(3): 207-211.